Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine to $132 from $130 and keeps a Buy rating on the shares. The firm said its results showed solid execution and upcoming catalysts continue to underpin their thesis.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target raised to $135 from $127 at Cantor Fitzgerald
- Neurocrine price target raised to $125 from $120 at TD Cowen
- Neurocrine price target raised to $112 from $111 at Mizuho
- Neurocrine price target raised to $148 from $140 at Baird
- Neurocrine raises 2023 net product sales view to $1.77B-$1.82B